Skip to main content
All Posts By

Justin Cesnavicius

Pharma Follows Moving Demographics CMC ConsultinghealthcarePharmaceutical Industry
June 19, 2025

Pharma Follows Moving Demographics

Changing Demographics Are Reshaping the Pharmaceutical Industry Demographic changes are transforming the pharmaceutical landscape, influencing everything from drug development priorities to global market dynamics. The increasing median age of populations, declining birth rates, and the rapid evolution of emerging economies present both challenges and strategic opportunities. In this context, agile CMC guidance and advanced digital solutions have become critical differentiators for pharmaceutical companies aiming to stay competitive. Aging Populations and the Demand for Chronic Disease Treatments Global populations are rapidly shifting toward an older median age. Over the next 75 years, the population of those aged 65 and older is projected to nearly quadruple from 650 million to an estimated 2.5 billion. This trend exacerbates demand for therapies targeting: Cardiovascular diseases (CVDs): As the leading global cause of death, CVDs continue to drive demand for advanced therapies and long-term monitoring technologies. The risk of CVD increases from about 40% in 40-59 years to about 75% from 60-79 in men and…
Justin Cesnavicius 0
Love0
BARDA: Fostering the Public-Private Connection Uncategorised
May 15, 2025

BARDA: Fostering the Public-Private Connection

In an ever-evolving landscape of public health emergencies and biological threats, the importance of collaborative efforts between the public and private sectors cannot be overstated. Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR), an arm of U.S. Department of Health and Human Services, has emerged as a crucial player in fostering partnerships to advance the development of medical countermeasures. In this blog, we will explore how BARDA collaborates with both the private and public sectors to drive innovation and preparedness. Some examples, past and present, will be provided to illustrate the diverse partnerships BARDA has established with the private sector to drive innovation, accelerate development, and strengthen manufacturing and distribution capabilities for medical countermeasures.   Private and Public Sector Collaboration   BARDA recognizes that effective preparedness and response require bridging the gap between the private and public sectors. It actively seeks partnerships with pharmaceutical companies, biotech firms, academia, and other…
Justin Cesnavicius 0
Love0
Big Data Meets Big Pharma BusinessData ManagementPharmaceutical Development
June 7, 2024

Big Data Meets Big Pharma

Burgeoning Data The amount of data generated daily has grown exponentially in recent history. According to an article by Fabio Duarte, almost 329 million terabytes of data are generated each day, totaling 120 zettabytes annually (1 zettabyte = 1,000,000,000,000,000,000,000 bytes). Sensors on manufacturing equipment generate data based on current conditions and equipment performance. IoT devices can process this data to make immediate adjustments for optimal performance, quality, and regulatory compliance. Processing this “big data” efficiently can be a major source of competitive advantage for pharma companies. Big Data Analytics Aggregated data generated by equipment-bound sensors can differ from the data found in traditional datasets and processed by analytical methods. Traditional analysis focuses on static data and historical trends but is less effective with high-volume, real-time data. Data veracity is vital to transforming data into usable information; big datasets have a huge pool of data to offset outliers and reduce human error during analysis. Big data frameworks like open-sourced Hadoop and…
Justin Cesnavicius 0
Love0
Close Menu